ALS patients with high numbers of circulating regulatory T cells appear to live longer and exhibit slower disease progression than most ALS patients. Could boosting the number of regulatory T cells be beneficial for all ALS patients? Increasing evidence from Phase I and II studies in patients undergoing stem cell transplantation to prevent graft vs. host disease (GVHD) suggests that treatment with low doses of interleukin-2 (IL-2) boosts regulatory T cell numbers. This will now be tested in ALS patients in a Phase I/II randomized, placebo-controlled clinical trial that will be starting in April 2014 under the direction of Gilbert Bensimon from Assistance Publique – Hôpitaux de Paris.
Click here to read more about low-dose IL-2 therapy and this upcoming clinical trial in France.Share this: